methyl 5-(5-amino-1,3,4-thiadiazol-2-yl)pentanoate | 227958-80-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl 5-(5-amino-1,3,4-thiadiazol-2-yl)pentanoate
• CAS: 227958-80-7
• 化学式: C₈H₁₃N₃O₂S
• 分子量: 215.276
• InChiKey: GIYFUMYZTWLCRR-UHFFFAOYSA-N

物化性质

• 沸点：
  358.8±44.0 °C(Predicted)
• 密度：
  1.266±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 5-(5-amino-1,3,4-thiadiazol-2-yl)pentanoate 在 三乙胺 、 lithium hydroxide 、 三氯氧磷 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 52.0h， 生成 N-[5-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-1,3,4-thiadiazol-2-yl]-2-phenylpropanamide
  参考文献：
  名称：

  Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors

  摘要：

  Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) is a potent and selective allosteric inhibitor of kidney-type glutaminase (GLS) that has served as a molecular probe to determine the therapeutic potential of GLS inhibition. In an attempt to identify more potent GLS inhibitors with improved drug-like molecular properties, a series of BPTES analogs were synthesized and evaluated. Our structure activity relationship (SAR) studies revealed that some truncated analogs retained the potency of BPTES, presenting an opportunity to improve its aqueous solubility. One of the analogs, N-(5-{2-[2-(5-amino-[1,3,4]thiadiazol-2-yl)-ethylsulfanyl]-ethyl}-[1,3,4]thiadiazol-2-yl)-2-phenylacetamide 6, exhibited similar potency and better solubility relative to BPTES and attenuated the growth of P493 human lymphoma B cells in vitro as well as in a mouse xenograft model.

  DOI：

  10.1021/jm301191p
• 作为产物：
  描述：

  甲基脂肪酰氯 在 硫酸 、 三氯氧磷 作用下， 反应 53.0h， 生成 methyl 5-(5-amino-1,3,4-thiadiazol-2-yl)pentanoate
  参考文献：
  名称：

  Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors

  摘要：

  Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) is a potent and selective allosteric inhibitor of kidney-type glutaminase (GLS) that has served as a molecular probe to determine the therapeutic potential of GLS inhibition. In an attempt to identify more potent GLS inhibitors with improved drug-like molecular properties, a series of BPTES analogs were synthesized and evaluated. Our structure activity relationship (SAR) studies revealed that some truncated analogs retained the potency of BPTES, presenting an opportunity to improve its aqueous solubility. One of the analogs, N-(5-{2-[2-(5-amino-[1,3,4]thiadiazol-2-yl)-ethylsulfanyl]-ethyl}-[1,3,4]thiadiazol-2-yl)-2-phenylacetamide 6, exhibited similar potency and better solubility relative to BPTES and attenuated the growth of P493 human lymphoma B cells in vitro as well as in a mouse xenograft model.

  DOI：

  10.1021/jm301191p

文献信息

• Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold
  作者：Sarah C. Zimmermann、Emily F. Wolf、Andrew Luu、Ajit G. Thomas、Marigo Stathis、Brad Poore、Christopher Nguyen、Anne Le、Camilo Rojas、Barbara S. Slusher、Takashi Tsukamoto

  DOI：10.1021/acsmedchemlett.6b00060

  日期：2016.5.12

  A series of allosteric kidney-type glutaminase (GLS) inhibitors were designed and synthesized using 1,4-di(5-amino-1,3,4-thiadiazol-2-yl)-butane as a core scaffold. A variety of modified phenylacetyl groups were incorporated into the 5-amino group of the two thiadiazole rings in an attempt to facilitate additional binding interactions with the allosteric binding site of GLS. Among the newly synthesized compounds, 4-hydroxy-N-[5-[4-[5-[(2-phenylacetypamino]-1,3,4-thiadiazol-2-yl]butyl]-1,3,4-thiadiazol-2-yl]-benze-neacetamide, 2m, potently inhibited GLS with an IC50 value of 70 nM, although it did not exhibit time-dependency as seen with CB-839. Antiproliferative effects of 2m on human breast cancer lines will be also presented in comparison with those observed with CB-839.
• [EN] PIPERAZINE DERIVATIVES USEFUL AS HYPOGLYCEMIC AGENTS<br/>[FR] DERIVES DE PIPERAZINE POUVANT ETRE UTILISES COMME AGENTS HYPOGLYCEMIQUES
  申请人：SHAMAN PHARMACEUTICALS, INC.

  公开号：WO1999031096A1

  公开（公告）日：1999-06-24

  (EN) Piperazine derivatives useful as antihyperglycemic agents, pharmaceutical compositions comprising the piperazine derivatives and methods for their use are described. The piperazine derivatives are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).(FR) L'invention concerne des dérivés de pipérazine présentant une grande utilité comme agents antihyperglycémiques. L'invention traite également de compositions pharmaceutiques comprenant des dérivés de pipérazine et des procédés d'utilisation de ces derniers. Les dérivés de pipérazine permettent de traiter le diabète sucré insulinodépendant (ou de type I) et le diabète sucré non insulinodépendant (ou de type II).
• Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors
  作者：Krupa Shukla、Dana V. Ferraris、Ajit G. Thomas、Marigo Stathis、Bridget Duvall、Greg Delahanty、Jesse Alt、Rana Rais、Camilo Rojas、Ping Gao、Yan Xiang、Chi V. Dang、Barbara S. Slusher、Takashi Tsukamoto

  DOI：10.1021/jm301191p

  日期：2012.12.13

  Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) is a potent and selective allosteric inhibitor of kidney-type glutaminase (GLS) that has served as a molecular probe to determine the therapeutic potential of GLS inhibition. In an attempt to identify more potent GLS inhibitors with improved drug-like molecular properties, a series of BPTES analogs were synthesized and evaluated. Our structure activity relationship (SAR) studies revealed that some truncated analogs retained the potency of BPTES, presenting an opportunity to improve its aqueous solubility. One of the analogs, N-(5-2-[2-(5-amino-[1,3,4]thiadiazol-2-yl)-ethylsulfanyl]-ethyl}-[1,3,4]thiadiazol-2-yl)-2-phenylacetamide 6, exhibited similar potency and better solubility relative to BPTES and attenuated the growth of P493 human lymphoma B cells in vitro as well as in a mouse xenograft model.